Compare Newmont Corporation (NEM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Newmont CorporationTrade

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Newmont Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Newmont Corporation trades at $127.77 (market cap $135.62B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Newmont Corporation pays a 0.81% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.

	NEM	XBI
Market Cap	$135.62B	—
Sector	Basic Materials	Broad Market / Factor
52-Week High	$135.14	$169.55
52-Week Low	$78.32	$93.43
Enterprise Value	$132.21B	—
Dividend Yield	0.81%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Newmont Corporation

NEM trades at $127.09, down 0.78% on the day, with a bullish technical signal and strong fundamental momentum. Revenue grew to $22.67B in 2025, with net income surging to $7.09B, and Q2 2026 EPS beat expectations at $2.10. Analyst consensus is strongly bullish with a $134.63 price target, supported by record free cash flow and institutional buying.

Outlook remains positive given earnings beats and gold's safe-haven appeal, but production challenges and cost pressures pose risks. The stock offers growth from operational strength and shareholder returns, yet investors face volatility from commodity prices and execution hurdles.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NEM

Bernstein lowers Newmont's price target amid gold production decline and rising costs.Andrew Wynn · 22 hours agoBearish View details →

XBI

Biotech ETF IBB outperformed S&P 500 by 22 points in 3 months amid pharma patent cliff deals.24/7 Wall Street · 2 days agoBullish State Street SPDR S&P Biotech ETF (XBI) rated Buy with 8%-14% returns expected despite prior 76% rallySeeking Alpha · 4 days agoBullish View details →

About Newmont Corporation

Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.